Voriconazole is used for long-term prophylaxis or treatment of fungal infections. Voriconazole-induced phototoxic effects and photocarcinogenesis is an independent risk factor for squamous cell carcinoma (SCC) development in organ transplant recipients.1 An alternative for patients at risk for cutaneous cancer has not been well studied. We describe a patient with voriconazole-induced photocarcinogenesis whose symptoms and tumor count improved after substitution with posaconazole.
Jacobsen AA, Papo YB, Sarro R, Weisse K, Strasswimmer J. Posaconazole Substitution for Voriconazole-Associated Phototoxic Effects. JAMA Dermatol. 2016;152(7):839-841. doi:10.1001/jamadermatol.2016.0345